| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.6 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |